Biotech News

Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update

Gain Therapeutics (GANX)Gain TherapeuticsEarnings

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update.

Related news

Gain Therapeutics

Allosteric Small-Molecule Platform Gain Therapeutics uses its Magellan discovery platform to identify allosteric small molecules that restore the function of disease-associated proteins. Its lead efforts focus on neurodegenerative disorders. GT-02287 GT-02287 is an oral, brain-penetrant modulator of glucocerebrosidase being developed for...

Recent company news

Stock data

Close
1.05 USD
Market cap
78.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States